# EDGAR Filing Document

**Accession Number:** 0002039072
**File Stem:** 0001683168-26-000062
**Filing Date:** 2026-1
**Character Count:** 7377
**Document Hash:** 3b6ee2df4afbdb0d1864bb36c02f1354
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001683168-26-000062.hdr.sgml**: 20260105

**ACCESSION NUMBER**: 0001683168-26-000062

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260105

**FILED AS OF DATE**: 20260105

**DATE AS OF CHANGE**: 20260105

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** DAVION HEALTHCARE PLC
- **CENTRAL INDEX KEY:** 0002039072
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** G4
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42981
- **FILM NUMBER:** 26503961

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** THE CUBE BUILDING
- **STREET 2:** MONAHAN ROAD
- **CITY:** CORK
- **PROVINCE COUNTRY:** L2
- **ZIP:** T12 H1XY
- **BUSINESS PHONE:** 357 25040052

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** THE CUBE BUILDING
- **STREET 2:** MONAHAN ROAD
- **CITY:** CORK
- **PROVINCE COUNTRY:** L2
- **ZIP:** T12 H1XY

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**FORM 6-K**

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR lSd-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

January 5th, 2026

File Number 333-289205

**DAVION HEALTHCARE PLC**

(Translation of registrant's name into English)

The Cube

Monahan Road

Cork

T12 H1XY

Ireland

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F □

Davion Healthcare Plc (the "Company") hereby furnishes the following information under Form 6-K:

**Amendment to NeuRX Licence Agreement**

Davion Healthcare Plc (the "Company") announces that on December 28th, 2025, it executed an Addendum with NeuRX Inc. to the existing Global Manufacturing and Distribution Licence Agreement.

The Addendum makes the following administrative amendments:

The commencement date of the Agreement has been revised to the start of the second half of 2026.

The commencement of scheduled payments to the Company, originally expected to begin in December 2025, has also been aligned with the new commencement date and will now begin in July 2026.

No other terms, conditions, obligations, or commercial provisions of the Agreement have been amended, and all other aspects of the Agreement remain in full force and effect.

The original Agreement, dated October 8th, 2025, was previously filed as Exhibit 10.3 to the Company's Form F-1 (File No. 333-289205) filed on November 7th, 2025, and is incorporated herein by reference.

**Exhibit**

A copy of Addendum No.1 is furnished herewith as [Exhibit 99.1](davion_ex9901.htm) to this Report on Form 6-K.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: January 5th, 2026

**Davion Healthcare Plc**

By: /s/ *Jack Kaye*

Name: Jack Kaye

Title: Chief Executive Officer

## Exhibit 99.1

**Exhibit 99.1**

**ADDENDUM NO. 1**

**TO THE GLOBAL MANUFACTURING AND DISTRIBUTION AGREEMENT<br> *(Dated 8 October 2025)*<br>** 

<br> This **Addendum No. 1** ("Addendum") is made and entered into as of **December 28<sup>th</sup>, 2025**, by and between:

**Davion Healthcare Plc**, a public limited company incorporated in Ireland ("Licensor"),<br> and<br> **NeuRX Health Inc.**, a corporation incorporated in the State of Rhode Island, USA ("Distributor").

Licensor and Distributor are each a "Party" and together the "Parties."

**RECITALS**

**WHEREAS**, the Parties entered into a *Global Manufacturing and Distribution Agreement* dated **8 October 2025** (the "Agreement"); and

**WHEREAS,** the Parties desire to amend the Agreement for the limited purpose of **revising the commencement of the Agreement's operational date and aligning the commencement of scheduled payments** accordingly; and

**WHEREAS,** except as expressly amended herein, the Parties intend that **all other terms, obligations, covenants, rights, and responsibilities under the Agreement shall remain unmodified and in full force and effect**.

**NOW, THEREFORE**, in consideration of the mutual covenants contained herein, the Parties agree as follows:

**1. Amendment to Article 1.4 (Operational Date)**

Article **1.4** of the Agreement, which defines the *Operational Date*, is hereby **deleted in its entirety** and replaced with the following:

**"1.4 'Operational Date' means 1 July 2026, being the revised start of the Contractual Year for the calculation of royalties, licence payments, and all associated commercial obligations."**

**2. Amendment to Article 4 (License Fee Timing)**

The Parties agree that the payment schedule in **Article 4.1(a)** and **4.1(b)** shall be amended such that:

**2.1 Revised Payment Commencement**

All payments originally scheduled to commence on:

· **1 December 2025**, and

· **1 January 2026** 

are hereby amended to commence on:

**1 July 2026**, aligned with the revised Operational Date.

**2.2 No Change to Total License Fee**

The total license fee of **USD $120,000,000** remains unchanged, with only the **timing** of the initial cash payment and instalments adjusted as above.

**3. Amendment to Schedule A – Payment Timetable**

Schedule A of the Agreement is amended only as follows:

**3.1 Cash Payment Revision**

The following shall replace the first two bullet points in Section 1 of Schedule A:

· **USD $1,000,000** payable in full on or before **1 July 2026**.

· **USD $19,000,000** payable in twelve (12) equal monthly instalments commencing **1 August 2026** and concluding **30 July 2027**.

**3.2 Share Issuance Timing**

Share issuances originally scheduled to commence on **1 January 2026** shall instead commence on:

**1 January 2027**, with each of the ten annual USD $10,000,000 issuances shifting forward by exactly one year.

No other changes are made to the form, nature, or structure of share issuances.

**4. No Other Amendments**

Except as expressly amended by this Addendum:

· The Agreement remains **unaltered**,

· The Agreement remains in **full force and effect**,

· All rights and obligations of the Parties continue uninterrupted.

For clarity, **all commercial, IP, regulatory, royalty, minimum royalty, manufacturing, audit, indemnification, and termination provisions** remain unchanged.

**5. Miscellaneous**

5.1 **Counterparts.** This Addendum may be executed in counterparts, including electronically, each of which shall be deemed an original.<br> 5.2 **Defined Terms.** Capitalised terms not defined herein shall have the meanings assigned in the Agreement.<br> 5.3 **Governing Law.** This Addendum shall be governed by the same governing law clause stated in Article 15.1 of the Agreement.

**SIGNATURES**

**For and on behalf of Davion Healthcare Plc**

By*: /s/ David Over*

Name: David Over<br> Title: Chief Commercial Officer

Date: December 28<sup>th</sup>, 2025

**For and on behalf of NeuRX Health Inc.**

By: */s/ Robert Hainey*

Name: Robert Hainey<br> Title: Chief Executive Officer

Date: December 28<sup>th</sup>, 2025